GET3
Basic information
Region (hg38): 19:12737139-12748323
Previous symbols: [ "ASNA1" ]
Links
Phenotypes
GenCC
Source:
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Cardiomyopathy, dilated, 2H | AR | General | Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing | Cardiovascular | 31461301 |
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the GET3 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 0 | |||||
missense | 20 | 20 | ||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 0 | |||||
non coding | 0 | |||||
Total | 0 | 0 | 20 | 0 | 0 |
Variants in GET3
This is a list of pathogenic ClinVar variants found in the GET3 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
19-12737528-G-C | not specified | Uncertain significance (Sep 30, 2022) | ||
19-12737533-G-T | not specified | Uncertain significance (Feb 06, 2023) | ||
19-12737591-G-A | not specified | Uncertain significance (Oct 26, 2024) | ||
19-12737608-C-T | not specified | Uncertain significance (Oct 09, 2024) | ||
19-12738542-C-T | not specified | Uncertain significance (May 24, 2023) | ||
19-12738543-G-A | not specified | Uncertain significance (May 26, 2024) | ||
19-12738573-C-G | Prostate cancer | Uncertain significance (-) | ||
19-12738593-G-A | not specified | Uncertain significance (Jan 22, 2025) | ||
19-12738629-G-A | not specified | Uncertain significance (Jul 05, 2023) | ||
19-12745398-G-A | not specified | Uncertain significance (Dec 16, 2024) | ||
19-12745402-C-T | not specified | Uncertain significance (Mar 04, 2024) | ||
19-12745405-A-G | not specified | Uncertain significance (Jul 27, 2024) | ||
19-12745622-A-G | not specified | Uncertain significance (Nov 15, 2021) | ||
19-12745638-T-C | Cardiomyopathy, dilated, 2H | Pathogenic (Jan 23, 2025) | ||
19-12747206-A-T | not specified | Uncertain significance (Mar 02, 2023) | ||
19-12747269-G-A | not specified | Uncertain significance (Nov 10, 2022) | ||
19-12747276-G-A | not specified | Uncertain significance (May 24, 2023) | ||
19-12747527-G-A | not specified | Uncertain significance (Mar 23, 2023) | ||
19-12747530-C-T | not specified | Uncertain significance (Sep 24, 2024) | ||
19-12747533-G-A | not specified | Uncertain significance (Aug 10, 2021) | ||
19-12747544-C-G | - | no classification for the single variant (-) | ||
19-12747587-G-C | not specified | Uncertain significance (Apr 29, 2024) | ||
19-12747590-C-T | - | no classification for the single variant (-) | ||
19-12748000-A-G | not specified | Uncertain significance (May 30, 2024) | ||
19-12748013-C-T | not specified | Uncertain significance (Nov 13, 2024) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
GET3 | protein_coding | protein_coding | ENST00000591090 | 7 | 11185 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.943 | 0.0568 | 125741 | 0 | 3 | 125744 | 0.0000119 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 2.21 | 120 | 210 | 0.571 | 0.0000119 | 2307 |
Missense in Polyphen | 15 | 65.723 | 0.22823 | 782 | ||
Synonymous | -0.801 | 100 | 90.3 | 1.11 | 0.00000575 | 670 |
Loss of Function | 3.15 | 1 | 13.5 | 0.0742 | 5.70e-7 | 167 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.00 | 0.00 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.000109 | 0.000109 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.00 | 0.00 |
Middle Eastern | 0.000109 | 0.000109 |
South Asian | 0.0000327 | 0.0000327 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: ATPase required for the post-translational delivery of tail-anchored (TA) proteins to the endoplasmic reticulum. Recognizes and selectively binds the transmembrane domain of TA proteins in the cytosol. This complex then targets to the endoplasmic reticulum by membrane-bound receptors, where the tail- anchored protein is released for insertion. This process is regulated by ATP binding and hydrolysis. ATP binding drives the homodimer towards the closed dimer state, facilitating recognition of newly synthesized TA membrane proteins. ATP hydrolysis is required for insertion. Subsequently, the homodimer reverts towards the open dimer state, lowering its affinity for the membrane-bound receptor, and returning it to the cytosol to initiate a new round of targeting (By similarity). May be involved in insulin signaling. {ECO:0000255|HAMAP-Rule:MF_03112, ECO:0000269|PubMed:17382883, ECO:0000269|PubMed:18477612, ECO:0000269|PubMed:25535373}.;
- Pathway
- XBP1(S) activates chaperone genes;IRE1alpha activates chaperones;Unfolded Protein Response (UPR);Metabolism of proteins
(Consensus)
Recessive Scores
- pRec
- 0.178
Intolerance Scores
- loftool
- 0.361
- rvis_EVS
- -0.54
- rvis_percentile_EVS
- 20.26
Haploinsufficiency Scores
- pHI
- 0.390
- hipred
- Y
- hipred_score
- 0.685
- ghis
- 0.633
Essentials
- essential_gene_CRISPR
- E
- essential_gene_CRISPR2
- E
- essential_gene_gene_trap
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.963
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Asna1
- Phenotype
- mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span);
Zebrafish Information Network
- Gene name
- asna1
- Affected structure
- retinal outer plexiform layer
- Phenotype tag
- abnormal
- Phenotype quality
- morphology
Gene ontology
- Biological process
- posttranslational protein targeting to endoplasmic reticulum membrane;arsenite transport;IRE1-mediated unfolded protein response;tail-anchored membrane protein insertion into ER membrane
- Cellular component
- nucleus;nucleolus;cytoplasm;endoplasmic reticulum membrane;GET complex;extracellular exosome
- Molecular function
- transporter activity;protein binding;ATP binding;arsenite transmembrane transporter activity;ATPase activity;metal ion binding